Most Read Articles
Kathlin Ambrose, 12 Nov 2015
The outcome for patients experiencing out-of-hospital sudden cardiac arrest (OSCA) remains very poor in Malaysia. Local data shows that return of spontaneous circulation in OSCA patients stands at 17.4 percent, while survival to ward is a mere 4.3 percent. [Med J Malaysia 2008; 63:4–8]
Tristan Manalac, 2 days ago
Contrary to conventional knowledge, consumption of dairy products appears to reduce the risk of major cardiovascular disease events and mortality, according to a recent multinational study.
Pearl Toh, 17 Sep 2018
Lifestyle interventions incorporating diet and exercise slash the need for antihypertensive medications by more than half among overweight or obese adults with high blood pressure (BP), according to a secondary analysis of the ENCORE trial presented at the Joint Hypertension 2018 Scientific Sessions.
Christina Lau, 31 Aug 2018

Daily low-dose aspirin is not beneficial for primary prevention of cardiovascular (CV) events in patients with diabetes or moderate CV risk, according to results of the ASCNED and ARRIVE trials reported at the European Society of Cardiology (ESC) Congress 2018.

Current smoking ups death, hospitalization in HFpEF patients

12 Sep 2018

Current smoking increases the likelihood of adverse outcomes in patients with heart failure with preserved ejection fraction (HFpEF), a recent study has shown.

Researchers analysed 1,717 patients with HFpEF (mean age 71±10 years; 50 percent male), most of whom (51 percent; n=871) were former smokers. Seven percent (n=116) and 42 percent (n=729) were current and never smokers, respectively.

Over a median follow-up period of 2.9 years, researchers observed 387 hospitalizations for heart failure. Cox regression analysis showed that compared with former smokers, current smokers were significantly more likely to be hospitalized for heart failure (hazard ratio [HR], 1.68; 95 percent CI, 1.08–2.61; p=0.02).

In the same time span, there were 374 deaths recorded, majority of which (n=218) were cardiovascular in nature. Relative to never smoking, current smoking was likewise associated with significantly higher risks of death (HR, 1.82; 1.19–2.78; p=0.0057) and cardiovascular death (HR, 1.85; 1.09–3.14; p=0.022).

No such effect was observed for former smoking compared with never smoking (hospitalization for heart failure: HR, 1.25; 0.99–1.57; p=0.053; death: HR, 1.02; 0.81–1.29; p=0.85; cardiovascular death: HR, 1.00; 0.74–1.35; p=0.99).

Analyses were adjusted for age, sex, race, body mass index, aspirin and antihypertensive medication use, systolic blood pressure, and comorbidities such as diabetes, chronic obstructive pulmonary disease, stroke and coronary heart disease.

Though further studies are needed to confirm these findings, the present results suggest that smoking cessation programmes may be beneficial to HFpEF patients, said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Kathlin Ambrose, 12 Nov 2015
The outcome for patients experiencing out-of-hospital sudden cardiac arrest (OSCA) remains very poor in Malaysia. Local data shows that return of spontaneous circulation in OSCA patients stands at 17.4 percent, while survival to ward is a mere 4.3 percent. [Med J Malaysia 2008; 63:4–8]
Tristan Manalac, 2 days ago
Contrary to conventional knowledge, consumption of dairy products appears to reduce the risk of major cardiovascular disease events and mortality, according to a recent multinational study.
Pearl Toh, 17 Sep 2018
Lifestyle interventions incorporating diet and exercise slash the need for antihypertensive medications by more than half among overweight or obese adults with high blood pressure (BP), according to a secondary analysis of the ENCORE trial presented at the Joint Hypertension 2018 Scientific Sessions.
Christina Lau, 31 Aug 2018

Daily low-dose aspirin is not beneficial for primary prevention of cardiovascular (CV) events in patients with diabetes or moderate CV risk, according to results of the ASCNED and ARRIVE trials reported at the European Society of Cardiology (ESC) Congress 2018.